News

10x Genomics price target lowered to $12 from $16 at BofA
BofA analyst Michael Ryskin lowered the firm’s price target on 10x Genomics (TXG) to $12 from $16 and keeps a Neutral rating on the shares.
StockStory.org on MSN8d
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump ...
10x Genomics price target lowered to $12 from $15 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $12 from $15 and keeps an Overweight rating on the ...
Forbes8d
10x Genomics
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
Longview News-Journal1mon
10x Genomics Secures Injunction Against Parse Biosciences' Planned ATAC Products
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.
Seeking Alpha28d
10x Genomics: Lower Cost Innovation May Drive A Rebound
Founded in 2012, 10x Genomics (NASDAQ:TXG) is a biotech company developing gene-sequencing solutions based in the US. In a rather competitive market, TXG’s focus has been on single-cell and ...
U.S. News & World Report4y
10x Genomics Inc - Ordinary Shares - Class A
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...